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ABSTRACT
Background and Objectives: We evaluated the inci-
dence of tumor recurrence following hand-assisted lapa-
roscopic nephroureterectomy (HALNU) for the treatment
of upper tract urothelial carcinoma.
Methods: The medical records of consecutive patients
who underwent HALNU by a single surgeon (CW) be-
tween October 2001 and May 2005 were reviewed. The
ureter was clipped before kidney dissection to prevent
distal migration of tumor. Following liberation of the kid-
ney, the bladder cuff and intramural ureter were excised
by using a Collings knife under cystoscopic guidance.
Results: Ten patients were identified. The primary loca-
tion of disease was confined to the intrarenal collecting
system. Eight high-grade (HG) and 2 low-grade (LG) tu-
mors were removed, with pT3 (6), pT2 (1), pT1 (1), and
pTa (2) disease. The patient having a LG pTa urothelial
carcinoma developed pulmonary metastasis 20 months
following surgery and survived an additional 26 months.
Two patients, each having a HG pT3 tumor, developed a
urothelial carcinoma in the bladder contralateral to the site
of ureteral excision. At a mean follow-up of 41 months,
there has been no evidence of tumor recurrence in the
pelvis.
Conclusion: Our technique of HALNU does not appear
to harbor an increased risk for urothelial carcinoma recur-
rence.
Key Words: Hand-assisted laparoscopic nephroureterec-
tomy, Urothelial carcinoma, Upper urinary tract, Transi-
tional cell carcinoma.
INTRODUCTION
Upper tract urothelial carcinoma is a relatively rare dis-
ease, accounting for 5% of all urothelial tumors.1 Open
nephroureterectomy with excision of the bladder cuff has
been the gold standard for treatment of this condition.2 It
is a major operation that requires 1 or 2 long abdominal
incisions and is associated with significant postoperative
morbidity and lengthy convalescence.
In the past decade, major advances have been made in
technology for minimally invasive surgery. Laparoscopy
for urologic oncologic surgery has gained wider accep-
tance. Laparoscopic nephroureterectomy (LNU) experi-
ence was first reported in 1995 by McDougall et al.3 Since
then, various institutions have described their experienc-
es.4–7 Convalescence, as measured by analgesic medica-
tion requirements and length of hospital stay, is signifi-
cantly better with laparoscopy, and the operative time and
specimen size for the 2 approaches are similar.7 Despite
this, some urologists remain reluctant to adopt this tech-
nique for treating upper tract urothelial carcinoma due to
its aggressive nature and the lack of controlled trials com-
paring laparoscopy with open surgery. Randomized trials
to evaluate the optimal method of managing the distal
ureter and bladder cuff have not been performed. Our
technique of hand-assisted laparoscopic nephroureterec-
tomy (HALNU) with cystoscopic en bloc excision of the
distal ureter and bladder cuff has been described.8 It
duplicates open surgical excision of these structures and
obviates bladder trocar placement and midprocedural pa-
tient repositioning.8 The risk of tumor seeding during
HALNU/LNU is questioned. Herein, we evaluate the inci-
dence of tumor recurrence following HALNU for the treat-
ment of upper tract urothelial carcinoma.
METHODS
The medical records of consecutive patients who under-
went HALNU by a single surgeon (CW) between October
2001 and May 2005 were reviewed. Details of the tech-
nique have been previously described.8 In brief, the ureter
is isolated and clipped before kidney dissection to prevent
distal migration of tumor. Following liberation of the kid-
ney, the bladder cuff and intramural ureter are excised
Department of Urology, University of Oklahoma Health Sciences Center, Okla-
homa City, Oklahoma, USA (Drs Araki, Lam, Wong).
Fetzer-Clair Urology Associates, Allentown, Pennsylvania, USA (Drs Fetzer, Clair).
Address reprint requests to: Carson Wong, MD, FRCSC, FACS, Department of
Urology, University of Oklahoma Health Sciences Center, 920 Stanton L Young
Blvd, WP 3150, Oklahoma City, OK, 73104, USA. Telephone: 405 271 6900, Fax:
405 271 3118, E-mail: carson-wong@ouhsc.edu
We are grateful to Beverly K. Shipman for her assistance in the preparation of this
manuscript.
© 2007 by JSLS, Journal of the Society of Laparoendoscopic Surgeons. Published by
the Society of Laparoendoscopic Surgeons, Inc.
JSLS (2007)11:449–452 449
SCIENTIFIC PAPERusing a Collings knife under cystoscopic guidance. With
the bladder left open, a urethral catheter is placed for
drainage. A gravity cystogram is obtained 7 days after
surgery; if normal, the urethral catheter is removed. Rou-
tine surveillance, consisting of cystoscopy, urine cytology,
computed tomography (abdomen and pelvis), and chest
radiography, at 3- (year 1–2), 6- (year 3–4) and 12-month
intervals after surgery is performed.
RESULTS
Ten patients were identified for study inclusion. Their
average age was 69 years (range, 49 to 83). Four (40%)
patients had a history of bladder urothelial carcinoma, but
there were no cases of ureteral disease. Visual confirma-
tion of urothelial carcinoma was established by ureteros-
copy in 10 (100%) patients. The pathologic diagnosis was
confirmed in 9 (90%) cases prior to surgery. No carcinoma
in situ was identified.
All cases were completed successfully without open con-
version. The mean estimated blood loss (EBL) was 210cc
(range, 100 to 500). Three immediate complications (2
major and 1 minor) occurred in 2 patients. One patient
(No. 2) required a blood transfusion postoperatively sec-
ondary to thrombocytopenia and coagulopathy. This pa-
tient had multiple blood transfusions for gross hematuria
before surgery. It was felt that the combination of multiple
blood transfusions and the surgical insult induced these
conditions, despite an EBL of 200 mL. The patient also had
diabetic nephropathy (creatinine 1.5 mg/dL) and devel-
oped acute on chronic renal failure (creatinine 3.5 mg/dL)
postoperatively. The creatinine peaked at 2.3 mg/dL with-
out the need for dialysis. His hospital stay was extended to
11 days. One patient (No. 3) had a skin dehiscence that
did not require surgical intervention. No other immediate
or delayed complications occurred. All urethral catheters
were removed 7 days after surgery.
The primary location of disease was mostly confined to
the intrarenal collecting system. One patient had multifo-
cal disease involving the renal pelvis and proximal ureter,
while another had a tumor in the proximal ureter only.
Eight high-grade (HG) and 2 low-grade (LG) tumors were
removed, with pT3(6), pT2(1), pT1(1), and pTa(2) dis-
ease. The mean tumor size was 3.1cm (range, 0.8 to 8).
At a mean follow-up of 41 months (range, 19 to 63), 8/10
patients remain tumor free. The patient having an LG pTa
urothelial carcinoma developed pulmonary metastasis 20
months following surgery (No. 6). With cisplatin-based
chemotherapy, this patient survived an additional 26
months before succumbing to the disease. Two patients
had tumor recurrence in the bladder [HG pT1(1), LG
pTa(1)] contralateral to the site of ureteral excision (No. 8
and 10). Both patients had a 6-week course of intravesical
BCG instillation. The patient having HG pT1 disease (No.
8) had a subsequent tumor recurrence (HG pTa) following
the initial course of BCG. A second 6-week course of BCG
treatment was provided. To date, both patients remain
tumor free. One patient died from a noncancerous pro-
cess 35 months following surgery (No. 5). There has been
no evidence of tumor recurrence in the pelvis as con-
firmed by serial computed tomography. Patient demo-
graphics and results are summarized in Table 1.
DISCUSSION
Laparoscopy has many reported advantages compared
with open surgery. These include decreased postopera-
tive use of parenteral narcotics, shorter hospitalization,
earlier time to oral intake, and earlier return to normal
activity. There is also no significant increase in operative
time for LNU versus open surgery.9–11
Despite these benefits, concerns have been raised over
the possibility of higher recurrence rates of urothelial
carcinoma when nephroureterectomy is performed lapa-
roscopically versus open surgery. The issue is how to
manage the distal ureter and bladder cuff. Many variations
of LNU and HALNU have been reported. Some centers
perform LNU or HALNU and utilize a Gibson incision to
manage the distal ureter. Recurrence rates from this ap-
proach have not been demonstrated to be significantly
increased.12,13 Gill et al5 described a laparoscopic ap-
proach with the use of 2 needlescopic bladder ports and
a cystoscopically placed Collings knife for bladder cuff
excision with endoloop occlusion before manipulation of
the upper tract. The recurrence rate for this technique with
a 2-year follow-up was no different than that of an open
approach.14–16 Another method is the “pluck” method as
described by Keeley and Tolley.17 There was no differ-
ence in local recurrence rates and long-term outcomes
compared with that of the open nephroureterectomy.18,19
In summary, there appears to be no significant difference
in local tumor control and recurrence rates between open
and laparoscopic nephroureterectomy. The only method
that appears to have a higher risk of tumor recurrence is
the one that utilizes a laparoscopic extravesical stapling
device to address the distal ureter. Matin et al15 recently
reported that the use of a laparoscopic extravesical stapler
is associated with a higher incidence of tumor recurrence
and positive surgical margin.
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tial excision of the distal ureter using a cystoscopically
placed Collings knife without primary closure of the blad-
der. This technique is similar to that of the University of
Miami as described by Wong and Leveillee.8 We, how-
ever, do not require an indwelling ureteral stent. Thus, the
ureter can be completely occluded with Hem-O-Lok
(Teleflex, Raleigh-Durham, NC) or titanium clips. The
bladder recurrence rate for this approach was recently
reported to be 49%, decreasing to 34% when corrected for
a history of bladder cancer.20
There appears to be no increased risk of bladder tumor
recurrence with this technique compared with open
nephroureterectomy. This is likely due to the early iden-
tification and clipping of the distal ureter before laparo-
scopic manipulation of the upper tract, which has the
potential to result in distal seeding of tumor cells. Despite
leaving the bladder cuff open, there also appears to be no
increased risk of tumor recurrence in the pelvis or port
sites. This may be explained by the fact that all of our
patients had intrarenal or proximal upper tract lesions.
Our HALNU technique has the advantage of eliminating
the need for patient repositioning during the procedure.
In addition, bladder ports are unnecessary. Finally, it sim-
plifies the management of the bladder cuff by eliminating
the need for primary closure of the resected site.
There are several limitations to our study. One drawback
is the small number of patients. All of the tumors were
located in the intrarenal collecting system or proximal
ureter. The recurrence rate may not be reflective of can-
cers occurring more distally. Our technique would not be
appropriate for distal ureteral tumors without compromis-
ing the oncologic principles of surgery.
CONCLUSION
Our HALNU technique with cystoscopic en bloc excision of
the distal ureter and bladder cuff for the management of
upper tract urothelial carcinoma appears to harbor no in-
creased risk for bladder or pelvic recurrence compared with
other laparoscopic or open techniques, despite leaving the
bladder open following bladder cuff excision. By clipping
the ureter prior to kidney dissection, risk of tumor spillage is
minimized. Despite the small number of patients, the finding
that this HALNU technique has no increased risk of urothelial
carcinoma recurrence lends further support to the use of
laparoscopic techniques for the treatment of this condition.
Table 1.
Patient Demographics
Patient
No.
Gender Age
(yrs)
ASA* EBL* OR
Time
(min)
Complications Tumor
Grade
Site of
Tumor
Tumor
Size
(cm)
Pathologic
Stage
Location
of
Recurrence
Follow-Up
Period
(mo)
1 F 58 2 150 487 None Low Renal pelvis 2.2 TaNxMx None 19
2 M 83 3 200 284 Coagulopathy,
Thrombocytopenia,
ARF
High Lower calyx 0.8 T3NxMx None 21
3 F 70 3 350 221 Wound
dehiscence
High Renal pelvis,
Proximal ureter
4.5 T3N0Mx None 24
4 F 59 2 100 310 None High Proximal ureter 2.1 T2NxMx None 25
5 M 68 3 250 268 None High Renal pelvis 1.0 T1NxMx None 35†
6 F 49 1 500 240 None Low Renal pelvis 2.2 TaNxMx Pulmonary 46†
7 M 78 2 200 280 None High Renal pelvis 4.0 T3N0Mx None 63
8 F 72 3 100 300 None High Renal pelvis 4.5 T3NxMx Bladder 58
9 M 71 2 100 277 None High Renal pelvis 2.0 T3N0Mx None 59
10 M 80 3 150 303 None High Renal pelvis 8.0 T3N0Mx Bladder 62
Summary M (5)
F (5)
69‡ 2.4‡ 210‡ 297‡ Major (2)
Minor (1)
High (8)
Low (2)
Renal pelvis (7)
Proximal ureter (1)
Lower calyx (1)
Multiple (1)
3.1‡ T3 (6)
T2 (1)
T1 (1)
Ta (2)
Pulmonary (1)
Bladder (2)
41‡
* ASA  American Society of Anesthesiologists risk index; EBL  estimated blood loss.
† Mortality.
‡ Mean.
JSLS (2007)11:449–452 451References:
1. Petersen RO. Renal pelvis. In: Urologic Pathology. Philadel-
phia, PA: JB Lippincott Co, 1986;181.
2. Cummings KB. Nephroureterectomy: rationale in the man-
agement of transitional cell carcinoma of the upper urinary tract.
Urol Clin North Am. 1980;7:569–578.
3. McDougall EM, Clayman RV, Elashry O. Laparoscopic
nephroureterectomy for upper tract transitional cell cancer: the
Washington University experience. J Urol. 154:975–979, 1995;
discussion 979–980.
4. Shalhav AL, Elbahnasy AM, McDougall EM, et al. Laparo-
scopic nephroureterectomy for upper tract transitional-cell can-
cer: technical aspects. J Endourol. 1998;12:345–353.
5. Gill IS, Soble JJ, Miller SD et al. A novel technique for
management of the en bloc bladder cuff and distal ureter during
laparoscopic nephroureterectomy. J Urol. 1999;161:430–434.
6. Keeley FX, Sharma NK, Tolley DA. Hand-assisted laparo-
scopic nephroureterectomy. BJU Int. 1999;83:504–505.
7. Stifelman MD, Hyman MJ, Shichman S, et al. Hand-assisted
laparoscopic nephroureterectomy versus open nephroureterec-
tomy for the treatment of transitional-cell carcinoma of the upper
urinary tract. J Endourol. 2001;15:391–397.
8. Wong C, Leveillee RJ. Hand-assisted laparoscopic
nephroureterectomy with cystoscopic en bloc excision of the
distal ureter and bladder cuff. J Endourol. 2002;16:329–333.
9. Shalhav AL, Dunn MD, Portis AJ, et al. Laparoscopic
nephroureterectomy for upper tract transitional cell cancer: the
Washington University experience. J Urol. 2000;163:1100–1104.
10. Kawauchi A, Fujito A, Ukimura O, et al. Hand assisted
retroperitoneoscopic nephroureterectomy: comparison with the
open procedure. J Urol. 169:890–894, 2003; discussion 894.
11. Doehn C, Fornara P, Fricke L, et al. Comparison of laparo-
scopic and open nephroureterectomy for benign disease. J Urol.
1998;159:732–734.
12. Klingler HC, Lodde M, Pycha A, et al. Modified laparoscopic
nephroureterectomy for treatment of upper urinary tract transi-
tional cell cancer is not associated with an increased risk of
tumour recurrence. Eur Urol. 2003;44:442–447.
13. Matsui Y, Ohara H, Ichioka K, et al. Retroperitoneoscopy-
assisted total nephroureterectomy for upper urinary tract transi-
tional cell carcinoma. Urology. 2002;60:1010–1015.
14. Gill IS, Sung GT, Hobart MG, et al. Laparoscopic radical
nephroureterectomy for upper tract transitional cell carcinoma:
the Cleveland Clinic experience. J Urol. 2000;164:1513–1522.
15. Matin SF, Gill IS. Recurrence and survival following laparo-
scopic radical nephroureterectomy with various forms of blad-
der cuff control. J Urol. 2005;173:395–400.
16. Stifelman MD, Sosa RE, Andrade A, et al. Hand-assisted
laparoscopic nephroureterectomy for the treatment of transi-
tional cell carcinoma of the upper urinary tract. Urology. 2000;
56:741–747.
17. Keeley FX Jr., Tolley DA. Laparoscopic nephroureterectomy:
making management of upper-tract transitional-cell carcinoma
entirely minimally invasive. J Endourol. 1998;12:139–141.
18. McNeill SA, Chrisofos M, Tolley DA. The long-term outcome
after laparoscopic nephroureterectomy: a comparison with open
nephroureterectomy. BJU Int. 2000;86:619–623.
19. Bariol SV, Stewart GD, McNeill SA, et al. Oncological control
following laparoscopic nephroureterectomy: 7-year outcome.
J Urol. 2004;172:1805–1808.
20. Kurzer E, Leveillee RJ, Bird VG. Combining hand assisted
laparoscopic nephroureterectomy with cystoscopic circumferen-
tial excision of the distal ureter without primary closure of the
bladder cuff—is it safe? J Urol. 2006;175:63–68.
Tumor Recurrence Incidence Following Hand-Assisted Laparoscopic Nephroureterectomy, Araki M et al.
JSLS (2007)11:449–452 452